Perry Amy, Soliman Karim, Andrade Erika, Mesmar Zaid, Overstreet Morgan, Fulop Tibor, Calimlim Isabel K, Harris Courtney, Taber David J
Medical Services, Ralph H. Johnson VA Medical Center, 109 Bee Street, Charleston, SC, 29401, USA.
Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Int Urol Nephrol. 2025 Jul;57(7):2227-2235. doi: 10.1007/s11255-025-04399-0. Epub 2025 Feb 4.
The goal of this study was to determine the secular trends in the incidence of CMV sero-mismatch (D+/R -) and if these trends meaningfully impact clinical outcomes.
This was a single-center longitudinal cohort study in adult kidney recipients transplanted between Jan 2012 and June 2021 with follow-up through June 2022. Baseline and follow-up data were collected. Univariate and multivariate statistics were used to analyze the data.
2,392 kidney transplants were performed during the study period; 132 patients did not meet inclusion criteria. The mean age was 52 years, 41% were female, 57% were black, and 19% were CMV D + /R -. The odds of being CMV high-risk increased by 6% each year (OR 1.06, 1.02-1.10 p = 0.003); 48% of the variability associated with CMV serostatus was explained by transplant year (R = 0.478, p = 0.002). Sequential modeling demonstrated that CMV D + /R - serostatus was a substantial risk factor for CMV infection (HR 5.7, 4.5-7.3), CMV disease (HR 8.4, 3.9-18.0), CMV resistance (HR 17.9, 3.8-84.2), CMV refractory infection (HR 35, 4-280), late CMV infection (HR 12.0, 8.3-17.1), acute rejection, and hospitalization for opportunistic infections. Secular trend analysis demonstrated that CMV infections, CMV resistance, and late CMV increased in incidence since 2012. The risks of CMV resistance and late infection was significantly influenced by D + /R - serostatus and transplant year, indicating that this risk is worsening over time.
The CMV D + /R - serostatus remains the single most important risk factor for CMV infection, disease, resistance, refractory infection, and late CMV, which appears to be increasing in magnitude.
本研究的目的是确定巨细胞病毒血清学不匹配(D+/R−)发生率的长期趋势,以及这些趋势是否对临床结果产生有意义的影响。
这是一项单中心纵向队列研究,研究对象为2012年1月至2021年6月间接受肾移植的成年患者,并随访至2022年6月。收集了基线和随访数据。使用单变量和多变量统计分析数据。
在研究期间共进行了2392例肾移植;132例患者不符合纳入标准。平均年龄为52岁,41%为女性,57%为黑人,19%为巨细胞病毒D+/R−。巨细胞病毒高风险的几率每年增加6%(OR 1.06,1.02 - 1.10,p = 0.003);与巨细胞病毒血清状态相关的48%的变异性可由移植年份解释(R = 0.478,p = 0.002)。序贯模型显示,巨细胞病毒D+/R−血清状态是巨细胞病毒感染(HR 5.7,4.5 - 7.3)、巨细胞病毒疾病(HR 8.4,3.9 - 18.0)、巨细胞病毒耐药(HR 17.9,3.8 - 84.2)、巨细胞病毒难治性感染(HR 35,4 - 280)、晚期巨细胞病毒感染(HR 12.0,8.3 - 17.1)、急性排斥反应和机会性感染住院的重要危险因素。长期趋势分析表明,自2012年以来,巨细胞病毒感染、巨细胞病毒耐药和晚期巨细胞病毒感染的发生率有所增加。巨细胞病毒耐药和晚期感染的风险受D+/R−血清状态和移植年份的显著影响,表明这种风险随时间推移正在恶化。
巨细胞病毒D+/R−血清状态仍然是巨细胞病毒感染、疾病、耐药、难治性感染和晚期巨细胞病毒感染的最重要单一危险因素,而且其影响程度似乎在增加。